Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Denosumab is protective against vertebral fractures among osteoporotic people with diabetes, reports a recent meta-analysis.
This is the first issue in a series of five
articles celebrating the fifth anniversary of EMPA-REG OUTCOME’s trial data
release. This issue brings insight to the trial’s background, study design and
key results.
In children with type 1 diabetes, small doses of subcutaneous glucagon appear to be safe and effective in preventing hypoglycaemic episodes in cases of nausea, vomit or food refusal, a study has shown.
Bariatric surgery lowers the risk of death in the long term compared with medical treatment alone when performed at age >43 years, but not at a younger age, in which the procedure may even increase mortality, as reported in a study. Nevertheless, weight-loss surgery confers benefits for morbidity across all age groups.
Use of pioglitazone is associated with a reduced risk of major adverse cardiovascular events (MACE) and is recommended in patients with or at high risk of type 2 diabetes (T2D), particularly those with a history of established cardiovascular disease (CVD), suggests a study.
Men with erectile dysfunction (ED) run a higher risk of death, suggested data presented at ENDO 2020.
Patients with type 2 diabetes mellitus (T2DM) who are overweight or obese but have high cardiorespiratory fitness (CRF)* may have a reduced risk of heart failure (HF), according to a study presented at EPI Lifestyle 2020.
Special Reports
This is the first issue in a series of five
articles celebrating the fifth anniversary of EMPA-REG OUTCOME’s trial data
release. This issue brings insight to the trial’s background, study design and
key results.
In a dinner symposium organised by Boehringer Ingelheim Malaysia, Dr Alice Cheng spoke on how cardiovascular outcome trials (CVOTs) have evolved and impacted the use of antihyperglycaemic agents such as sodium-glucosecotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in clinical practice.
At the AstraZeneca sponsored-symposium, held in conjunction with Diabetes Asia 2019, a panel of distinguished speakers spoke about the importance of preventing cardiovascular (CV) and renal complications in patients with type 2 diabetes mellitus (T2DM), in addition to addressing glucose control. Chaired by Professor Dato’ Dr Mafauzy Mohamed, the panel discussed updated outcomes of landmark studies supporting the benefit of dapagliflozin (Forxiga®, AstraZeneca) in patients with T2DM.
In a lecture tour series organised by Boehringer Ingelheim Malaysia, Professor Michael Cummings spoke on the latest linagliptin analyses that shed new light on the long-term safety profile of the dipeptidyl peptidase-4 (DPP-4) inhibitor across a broad range of patients with type 2 diabetes (T2D).
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
At a recent Boehringer Ingelheim-sponsored symposium held in conjunction with the 10th Malaysian Endocrine and Metabolic Society Annual Congress, two distinguished speakers spoke on the latest updates in glucose-lowering therapy for the treatment for type 2 diabetes mellitus (T2DM) and highlighted some important cardiovascular outcome trial results of these antidiabetic agents.
At the recent 10th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress(MAC) held in Hilton Kuala Lumpur, Dr Wong Ming, a consultant endocrinologist from Sunway Medical Centre, spoke on the role of non–high-density lipoprotein cholesterol (non–HDL-c) as an emerging marker and treatment target for cardiovascular (CV) disease. Additionally, she also highlighted the role of fenofibrate in delaying and preventing diabetic retinopathy (DR).
Conference Reports
Men with erectile dysfunction (ED) run a higher risk of death, suggested data presented at ENDO 2020.
Multiple analyses of the DAPA-HF* trial have shown that dapagliflozin, in addition to standard therapy, reduces the risk of multiple heart failure (HF) outcomes including cardiovascular (CV) death and hospitalization for HF (HHF) in patients with HF and reduced ejection fraction (HFrEF), with the effects consistent regardless of age and type 2 diabetes (T2D) status.
Slideshow: Highlights from the American Heart Association (AHA) Scientific Sessions 2019
Podcast: Professor Carolyn Lam states that dapagliflozin appears to meet the three major aims of HFrEF treatment, ie, reduced mortality, reduced hospitalization, and improved quality of life.
Podcast: Professor John McMurray says that the DAPA-HF trial demonstrates the efficacy of dapagliflozin in reducing the risk of heart failure in patients with HFrEF with and without T2D.
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Upfront combination therapy with metformin and the DPP-4* inhibitor vildagliptin may improve glycaemic durability in patients newly diagnosed with type 2 diabetes (T2D) compared with sequential therapy with metformin monotherapy followed by vildagliptin, results from the VERIFY** trial showed.
Multimedia
